Company: TELO
Filing Date: 2025-11-28
Form Type: PRER14A
Source: 0001493152-25-025406
Chunk: 50

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-28
Form: PRER14A
Chunk 50
---
 questions related to TELI’s pipeline, clinical development plans, the competitive landscape, regulatory and commercial considerations. Additionally, Moore provided TELO with a list of diligence questions related to TELI’s pipeline, clinical development plans, the competitive landscape, regulatory and commercial considerations.

In October 2025, TELO engaged Moore to conduct a valuation of TELO and TELI for determination of the Exchange Ratio. On October 8, 2025, a first draft of a Binding Letter of Intent (LOI) was circulated between TELO and TELI.

On October 1, 2025, TELO provided Moore with preliminary responses to Moore’s questions, including estimated completion dates and general and administrative expense forecasts required for Telomir-1 for each of Phase 1, Phase 2, Phase 2a and Phase 3 for the FDA process, quarterly research and development expense forecasts. detailed forecast of TELO’s research and development and general administrative expenses through 2027.

On October 8, 2025, after significant information discussion, William McNulty continued on behalf of TELI to negotiate the terms of the Merger with TELO.

On October 9, 2025 a revised draft of the LOI was circulated between TELO and TELI.

On October 10, 2025, the TELO Board held a meeting to discuss the LOI. Mr. Aminov provided a presentation on TELI’s business and explained the potential synergies between the two companies and market potential of Telomir-1. Mr. Aminov also explained to the TELO Board the conflicts of interests involved in the Merger. The terms of the LOI and the Telomir-1 Licensing Agreement were also discussed and reviewed. The TELO Board approved the Merger and the terms of the LOI.

At the October 10, 2025 meeting of the TELO Board, the TELO Board unanimously (i) determined that the Merger is fair to, advisable and in the best interests of TELO and its stockholders, and (ii) approved and declared advisable the Merger Agreement, including the issuance of shares of TELO Common Stock to the stockholders of TELI.

| 28 |

The TELO Board considered the following reasons in reaching its conclusion to approve the Merger Agreement and the Merger:

| ● | the                                                                                                                                 
 Board’s belief, after discussions with TELO’s senior management and legal counsel, that the Merger is more